Dogwood Therapeutics (DWTX)
Develops non-opioid therapies for chemotherapy-related neuropathic pain.
Something off on this page? Send us feedback.
Develops non-opioid therapies for chemotherapy-related neuropathic pain, led by injectable Halneuron and the licensed SP16 IV program. It has no commercial products and relies on outsourced clinical and manufacturing work and future pharmaceutical partners for commercialization.
Develops non-opioid therapeutics for cancer-associated pain and peripheral neuropathy, centered on Halneuron, a subcutaneous tetrodotoxin candidate that modulates the peripheral NaV1.7 channel. Its other internal program, SP16 IV, is an LRP1 agonist intended to limit inflammation and support neural repair during neurotoxic chemotherapy. Neither candidate has marketing approval, and neither produces revenue.
Operates from Georgia and Vancouver through a lean, outsourced model: contractors, CROs, and CMOs carry much of clinical and manufacturing execution, while the company expects pharmaceutical partners to commercialize approved products. Halneuron is the principal internally funded program; the former antiviral programs have been licensed to PRIDCor, leaving payments and royalties dependent on that partner's financing, development, and commercialization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.6M · Total debt $127.2K · Total assets $80.5M · Shareholders' equity $68.4M
- Revenue
- $0
- Operating income
- −$4.9M
- Net income
- −$11.5M
No dividends on record.
| Institutions13 holders · as of Mar 31, 2026 | 157.85% | 3.62M shares | |
| Adds to | 157.85% |
2.29M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.29M in the company's Sep 3, 2026 report, 33.63M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 157.85%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 143.03% | 3.28M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 5.76% | 132,154 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 3.46% | 79,434 | 13Fas of Mar 31, 2026 |
Vanguard Fiduciary Trust CoInstitution | 2.74% | 62,736 | 13Fas of Mar 31, 2026 |
Northern Trust CorpInstitution | 1.04% | 23,779 | 13Fas of Mar 31, 2026 |
| See all 14 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Teva (ADR)
Current duloxetine supplier in the painful-CIPN treatment benchmark.
- Vertex Pharmaceuticals
Non-opioid sodium-channel rival in peripheral neuropathic pain.
- Lexicon Pharmaceuticals
Phase 3 non-opioid challenger in chronic peripheral neuropathic pain.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dogwood Therapeutics | $2.47 | −0.40% | $83.4M | — | — | — | — |
| Teva (ADR) | $37.30 | −0.45% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Vertex Pharmaceuticals | $556.60 | −0.02% | $141.31B | 32.4 | 28.6 | 11.2 | +12.5% |
| Lexicon Pharmaceuticals | $2.25 | 0.00% | $995.0M | — | — | 24.0 | −97.6% |
| Median | 47.4 | 20.9 | 11.2 | −0.8% |